Clinical trials: Skin Infection
Tinea Pedis
A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.
To evaluate and compare the safety and efficacy of TA103 in the treatment of tinea pedis.
- Trial name
- NCT04883593
- Testing
- TA103
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Hidradenitis Suppurativa, Acne Inversa
A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa
This study further evaluates the efficacy of bermekimab in treating moderate to severe hidradenitis suppurativa in adults. 1/3 of patients will receive weekly injections of bermekimab, 1/3 will receive alternating every other…
- Conditions
- Hidradenitis Suppurativa, Acne Inversa, Suppurative Hidradenitis
- Trial name
- NCT04019041
- Testing
- bermekimab
- Where
- 33 sites in United States
- Volunteers
- 153 people
- Sponsor
- Janssen Research & Development, LLC
Herpes Labialis
Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis
This study will assess the safety, tolerability of a single 1500 mg dose of famciclovir in 50 adolescents with recurrent herpes labialis.
- Trial name
- NCT00878072
- Testing
- Famciclovir
- Where
- 12 sites in United States
- Volunteers
- 53 people
- Sponsor
- Novartis Pharmaceuticals
Common Warts
Active-Controlled Study to Assess the Efficacy and Safety of DFD-05 in Subjects With Common Warts
DFD05 vs. Active01 in the treatment of common warts
- Trial name
- NCT02798419
- Testing
- DFD05 Cream, Active01 Cream
- Where
- 12 sites in United States
- Volunteers
- 50 people
- Sponsor
- Dr. Reddys Laboratories, SA
Advanced Malignancies, Metastatic Cancer
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
- Trial name
- NCT03277352
- Testing
- INCAGN01876, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Biosciences International Sàrl
Hidradenitis Suppurativa
Real-world Secukinumab Outcomes in Canadian HS Patients
The HS-RISE study aims to assess real-world HS treatment outcomes and patterns, safety of secukinumab, and to describe the baseline characteristics of patients diagnosed with moderate-to- severe HS who are prescribed secukinumab…
- Trial name
- HS-RISE (NCT07282015)
- Where
- 15 sites in Canada
- Volunteers
- 142 people
- Sponsor
- Novartis Pharmaceuticals
Leishmaniasis
Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in Healthy Participants
This study is the first to test GSK3494245 in humans, to evaluate its safety, tolerability, and pharmacokinetics (PK) after a single dose.
- Trial name
- NCT04504435
- Testing
- GSK3494245
- Where
- United Kingdom
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Superficial Mycoses, Dermatomycoses
A Clinical Study to Evaluate the Pharmacokinetics of Lozanoc and Sporanox in Korean Healthy Male Volunteers
Study Objectives: To evaluate the pharmacokinetics (PK) of orally administered Lozanoc under fasted and fed condition in healthy male subjects To compare the pharmacokinetics (PK) of orally administered Lozanoc and Sporanox under…
- Conditions
- Superficial Mycoses, Dermatomycoses, Candidiasis, Histoplasmosis
- Trial name
- NCT02493738
- Testing
- Lozanoc 50mg, Sporanox 100mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Condylomata Acuminata
An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)
This study was conducted to demonstrate that Gardasil™ (quadrivalent human papillomavirus [qHPV] vaccine) 1) is well tolerated in young men, 2) reduces incidence of external genital lesions in young men, 3) reduces the incidence…
- Trial name
- NCT00090285
- Testing
- (Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
- Volunteers
- 4,065 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Onychomycosis
Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study
A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi- Site Phase 2b Clinical Study to Assess the Efficacy, Safety and Tolerability of 8-Week Regimens of NVXT topical product in Patients with Mild to Moderate…
- Trial name
- NCT02933879
- Testing
- NVXT topical
- Where
- United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Skin Diseases, Infectious
A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Adults With Uncomplicated Infections of the Skin and the Supportive Layers Beneath the Skin
The purpose of this study is to evaluate the safety and effectiveness of levofloxacin, an antibiotic, compared with another antibiotic, ciprofloxacin, in the treatment of adults with uncomplicated infections of the skin and the…
- Trial name
- NCT00257062
- Testing
- Levofloxacin
- Volunteers
- 361 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Pediculoses, Head Lice
Neem Lotion With Combing for Lice
This was a Phase IIa randomised, assessor blinded, parallel group study in which half the participants were treated with Nice 'n Clear neem-based conditioning lotion plus combing with a head louse detection and removal comb and…
- Trial name
- NCT02974088
- Testing
- Neem-based lotion plus louse comb, Neem-based lotion plus grooming comb
- Where
- United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Medical Entomology Centre
Papillomavirus Infections, Uterine Cervical Neoplasms
Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
This study will evaluate the safety and immunogenicity of V503 (GARDASIL™9, 9vHPV vaccine) administered to 9- to 26-year-old females and males in Vietnam.
- Conditions
- Papillomavirus Infections, Uterine Cervical Neoplasms, Vulvar Neoplasms, Vaginal Neoplasms
- Trial name
- NCT03546842
- Testing
- 9vHPV vaccine
- Where
- Vietnam
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Onychomycosis
Efficacy and Safety of Two Treatment Regimens of Topical MOB015 in Adults With Distal Subungual Onychomycosis
Onychomycosis is a fungal infection that affects fingernails and/or toenails. The purpose of this trial is to investigate if MOB015 is effective and safe for treatment of patients with fungal infection of the toenails.
- Trial name
- NCT01246518
- Testing
- MOB015
- Where
- Sweden
- Volunteers
- 250 people
- Sponsor
- Moberg Pharma AB
Onychomycosis
Efficacy and Safety Study of ME1111 in Patients With Onychomycosis
The purpose of the study is to determine the safety and efficacy of high and low strength of ME1111 solutions compared to the vehicle in the treatment of onychomycosis of the toenail.
- Trial name
- NCT02022215
- Testing
- ME1111 Solution, Low strength, ME1111 Solution, High strength, Matching Vehicle Solution
- Where
- 31 sites in United States
- Volunteers
- 304 people
- Sponsor
- Meiji Seika Pharma Co., Ltd.
Community Acquired Pneumonia (CAP), Complicated Skin and Skin Structures Infections (cSSSI)
Study Evaluating Management of Patients With Community-Acquired Pneumonia (CAP) or Complicated Skin Infections
This study will collect real-life data from patients with community acquired pneumonia (CAP) OR complicated skin and skin structure infections (cSSSI) to assess the burden of the disease, review the treatment pathways, evaluate…
- Trial name
- REACH (NCT01293435)
- Where
- 163 sites in Belgium, France and 8 more
- Volunteers
- 4,035 people
- Sponsor
- AstraZeneca
Common Wart
Safety Study of A-101 Topical Solution for the Treatment of Common Warts
A Phase 3 Study of A-101 Topical Solution Applied Twice a Week in Subjects with Common Warts
- Trial name
- NCT03812510
- Testing
- A-101
- Where
- 46 sites in United States
- Volunteers
- 426 people
- Sponsor
- Aclaris Therapeutics, Inc.
Non-bullous Impetigo
A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo
The purpose of this study is to determine the efficacy of the topical antibiotic LTX-109 in terms of clinical and microbiological response in treatment of impetigo.
- Trial name
- NCT01803035
- Testing
- LTX-109 1 %, LTX-109 2 %
- Where
- 2 sites in Dominican Republic
- Volunteers
- 210 people
- Sponsor
- Lytix Biopharma AS
Acute Bacterial Skin and Skin Structure Infection
A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
This was a Phase 4, multicenter, open-label safety study of a single 1200 milligrams (mg) IV infusion of oritavancin in adult participants on chronic warfarin with acute bacterial skin and skin structure infection (ABSSSI)…
- Trial name
- NCT02452918
- Testing
- Oritavancin, Warfarin
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- The Medicines Company
Rheumatoid Arthritis
Observational Real-world Evaluation of Cost of Infections of Rheumatoid Arthritis (RA) Patients on Biologics
To quantify the incremental cost of infections in patients treated with etanercept, adalimumab or infliximab versus abatacept.
- Trial name
- NCT01166620
- Volunteers
- 4,000 people
- Sponsor
- Bristol-Myers Squibb